NeurAxis (NASDAQ:NRXS – Get Free Report) and MariMed (OTCMKTS:MRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.
Insider and Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 0.2% of MariMed shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 17.3% of MariMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for NeurAxis and MariMed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
| MariMed | 0 | 2 | 0 | 0 | 2.00 |
Profitability
This table compares NeurAxis and MariMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeurAxis | -492.76% | N/A | -641.25% |
| MariMed | -9.13% | -10.71% | -2.58% |
Earnings and Valuation
This table compares NeurAxis and MariMed”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeurAxis | $5.32 million | 18.31 | -$14.63 million | ($0.78) | -9.94 |
| MariMed | $159.83 million | 0.19 | -$14.48 million | ($0.04) | -1.86 |
MariMed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than MariMed, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
NeurAxis has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, MariMed has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
Summary
NeurAxis beats MariMed on 8 of the 14 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About MariMed
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
